Noxopharm Limited (NOX) is a clinical-stage Australian drug development company with offices in Sydney and New York.
The company has a primary focus on the development of Veyonda and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.
Contact Details
Suite 3, Level 4
,
828 Pacific Hwy
GORDON
NSW
2072
02 9144 2223
info@noxopharm.com